Does Smoking Help Ulcerative Colitis? The Evidence

Smoking does not help ulcerative colitis in any way you can safely use. What is true is narrower and stranger than the forum version. In many studies people who currently smoke are less likely to develop ulcerative colitis, and people who have recently quit are more likely to, for years afterwards (Mahid 2006; Higuchi 2012). But once you already have the disease, a meta-analysis of 16 studies found that smokers did not have significantly fewer colectomies, flares, extensions of disease or cases of pouchitis (To 2016). And when researchers took nicotine out of the cigarette and tested it properly, it helped a little for a few weeks as an add-on, did nothing as a maintenance treatment, and caused enough side effects that it never became standard care.

This is one of the most persistent conversations in r/UlcerativeColitis. People describe their first symptoms arriving weeks or months after they quit, a doctor who "cannot recommend it but" mentioned the link, and a small but vocal group who went back to a few cigarettes a day during a flare and say it worked. We read those threads, then read every trial we could find. The research behind the folklore turns out to be small, old and more contradictory than either side of the argument admits, and in a couple of places the studies contradict their own abstracts. We print those contradictions below rather than smoothing them over.

If you have Crohn's disease rather than colitis, stop here and read does smoking make Crohn's worse instead: in Crohn's the direction reverses, and smoking is linked with more flares and more surgery. This article is about ulcerative colitis only. A note on method: when we say "we could find no study", that reflects our searching of PubMed and Europe PMC, not proof that none exists.

The short answer, split into the three questions people actually ask

Most confusion comes from three separate questions being answered as one. Here is each, with the strongest evidence we found and how confident you can be.

The rest of this article unpacks each row, and then covers the questions the Reddit threads keep returning to: what to do if your colitis started after quitting, whether patches, pouches or vapes count, and what you can do to make a quit attempt safer.

Is the "smokers get less colitis" finding real?

Probably partly, but it is weaker than its reputation. The most-cited pooled figure comes from a 2006 meta-analysis of 13 studies on UC, which found current smoking associated with lower odds of developing UC (odds ratio 0.58, 95% confidence interval 0.45 to 0.75) and former smoking with higher odds (1.79, 1.37 to 2.34) compared with never smoking (Mahid 2006). Most of those studies were case-control designs, where people with UC are asked about their past smoking. That design is vulnerable to recall problems and to who gets selected as a control.

The best prospective data tell a more interesting story. The Nurses' Health Studies followed 229,111 US women for up to 32 years, collected smoking status every two years, and confirmed 400 cases of UC from medical records. Compared with never smokers, current smokers had a hazard ratio for UC of 0.86, with a confidence interval of 0.61 to 1.20 that crosses 1, so no statistically significant protection. Former smokers had a hazard ratio of 1.56 (1.26 to 1.93). The risk was highest in the 2 to 5 years after stopping (3.06, 2.00 to 4.67) and remained raised for more than 20 years (Higuchi 2012).

A Japanese questionnaire study adds a different angle. Among 343 people with UC who responded, onset age showed a main peak in the teens and twenties and smaller peaks later in life, and former smokers were more likely to have a late onset at 50 or over (interaction odds ratio 2.93, 1.40 to 6.14) (Takahashi 2014). That fits the idea that some later-life UC arrives after a quit attempt. It is one hospital's patients and a questionnaire with a 74% response rate, so treat it as supportive rather than decisive.

The most sceptical evidence comes from genetics. A Mendelian randomisation study used gene variants linked to smoking behaviour to test whether smoking causes or prevents IBD, an approach that sidesteps some of the confounding in ordinary observational studies. It found no clear evidence that genetically predicted smoking initiation, cigarettes per day or smoking cessation were causally linked to UC. A possible association with age of starting smoking disappeared in sensitivity analyses (Georgiou 2021). Genetic instruments for smoking are imperfect, so this does not settle it, but it is a reason not to treat the protection story as proven.

Why this matters to you: if you already have UC, whether smokers are less likely to get it is mostly academic. The live questions are what quitting does and whether smoking changes the course of the disease you already have.

"My colitis started right after I quit." Is that a known pattern?

Yes. It is one of the most consistent findings in the whole area, and the threads are full of it. In one r/UlcerativeColitis thread asking how long after quitting people flared, replies ranged from a few weeks to about a year (r/UlcerativeColitis thread). In another, a long-time smoker with no bowel problems described being diagnosed three months after stopping, and several replies described the same sequence (r/UlcerativeColitis thread). The British guideline states that UC is more likely to arise in those who have recently quit, with the highest risk period in the first 2 to 5 years after stopping (Lamb 2019).

Three things are worth knowing about what that pattern does and does not mean.

It is an association, not a demonstrated cause. Nobody has shown the mechanism in people. One possibility raised in the threads is that smoking was masking a disease already present, and that stopping simply unmasked it. We could find no study that measured inflammation in smokers with no symptoms and then followed them through a quit, so that idea is plausible but untested.

It happens after diagnosis too. In a French cohort, 32 people who stopped smoking after their UC diagnosis were compared with themselves before quitting and with matched groups of 32 non-smokers and 32 continuing smokers. After quitting, the proportion of years with active disease, with hospital admission and with major treatment such as steroids or azathioprine all went up. Colectomy risk after quitting was similar to both comparison groups (Beaugerie 2001). That is 32 people at one specialist centre, followed for a mean of seven years, so it describes a pattern rather than predicting what will happen to you.

It is not a reason to regret quitting. Crohn's & Colitis UK and the British guideline reach the same conclusion: the risk of a flare after quitting is real, it is manageable with treatment, and it is smaller than the damage smoking does elsewhere. Crohn's & Colitis UK carries accounts from people who flared after quitting and were still glad they did (Crohn's & Colitis UK).

Once you have UC, does smoking make it milder?

The honest answer is that the studies disagree, and the pooled analysis says no significant difference. Here is what each side of the argument actually rests on.

The pooled evidence. A 2016 systematic review found 16 observational studies: five on colectomy (2,615 patients), four on flares (620), four on proximal disease extension (687) and three on pouchitis after pouch surgery (355). Compared with non-smokers, smokers' odds were 0.89 for colectomy (0.62 to 1.26), 1.26 for flare (0.65 to 2.44), 0.57 for extension (0.20 to 1.66) and 0.57 for pouchitis (0.21 to 1.53). Not one of those intervals excludes "no difference", and note that the point estimate for flares actually leans towards smokers doing worse. The authors concluded that smoking may not improve the natural history of UC and that cessation advice belongs in UC guidance (To 2016).

The studies that found a benefit. A French chart review of 556 people with UC found fewer smokers than non-smokers needed oral steroids (52% vs 63%, p = 0.05), and among people who started with limited disease, fewer smokers progressed to pancolitis (14% vs 26%) (Mokbel 1998). A Dutch questionnaire-plus-chart study of 295 people with UC reported lower rates of colectomy, primary sclerosing cholangitis and backwash ileitis in active smokers than in never smokers, with higher daily cigarette numbers linked to less extensive disease (van der Heide 2009).

The newer cohort. In the Sydney IBD cohort of 557 people with UC, current smokers used steroids less often (24.1% vs 37.5%, p = 0.045) but had no significant reduction in colectomy (3.4% vs 6.6%, p = 0.34) or hospital admission. Ex-smokers needed immunosuppressants more often (36.2% vs 26.3%, p = 0.041); their higher steroid use (43.7% vs 34.5%, p = 0.078) did not reach significance. The authors concluded the data "failed to demonstrate substantial benefit from smoking in UC" (Lunney 2015).

Crohn's & Colitis UK summarises this well: the studies showing benefit tend to be older and smaller, and the studies showing no effect are newer and larger but have their own weaknesses, so "at the moment we are not sure how smoking affects people's Ulcerative Colitis" (Crohn's & Colitis UK). That is a fair reading of everything above.

The nicotine trials, one by one

Since you cannot ethically randomise people to smoke, researchers in the 1990s did the next best thing: they took nicotine, the most obvious candidate, and tested it in controlled trials. These trials are the core of the evidence, and they are almost never described in detail outside journals. Here they are.

Sources for the table: Pullan 1994, Sandborn 1997, Thomas 1995, Thomas 1996, Green 1997, Ingram 2005, Lashner 1990.

The trial that started it: patches added to usual treatment

The Cardiff trial randomised 72 people with active UC to nicotine or placebo patches for six weeks, with the nicotine dose built up gradually. Everyone stayed on mesalamine, and 12 people also stayed on low-dose steroids. Complete remission came in 17 of 35 on nicotine and 9 of 37 on placebo. Nicotine also beat placebo on stool frequency (by 1.6 stools a day), abdominal pain, urgency, the clinician's global grade and the histology grade. The cost was side effects: 23 people on nicotine reported them against 11 on placebo, most often nausea, light-headedness, headache and sleep disturbance (Pullan 1994).

Do the subtraction. Remission was 48.6% on nicotine and 24.3% on placebo, so the gain attributable to nicotine was about 24 percentage points, not 49. A placebo arm in which a quarter of people went into remission is not a flaw; it is what active UC on mesalamine does over six weeks, and it is why controlled trials exist.

The US replication, and the word "improvement"

A Mayo Clinic trial randomised 64 non-smokers with mild to moderately active UC to patches at the highest tolerated dose or placebo for four weeks. At four weeks, 12 of 31 on nicotine showed clinical improvement against 3 of 33 on placebo (39% vs 9%, p = 0.007) (Sandborn 1997). That is a 30-point gain, but it is improvement, not remission, and pages that quote "39%" alongside the Cardiff remission figure are comparing different outcomes. Four people on nicotine stopped because of side effects: contact dermatitis in two, nausea in one and acute pancreatitis in one. The trial is listed in PubMed as having non-US-government support; we could not read a conflict-of-interest statement for it or for the Cardiff trials, since none is attached to the records, so we cannot say how any of them was funded.

Nicotine alone, as maintenance: no better than placebo

The same Cardiff group then asked whether patches could keep people in remission. They randomised 80 people in remission, built them up to a maintenance dose over three weeks, and then stopped their mesalamine, so nicotine or placebo was the only treatment. Over six months there was no significant difference in relapse: 14 people on nicotine and 17 on placebo were withdrawn because of relapse. Side effects were reported by 21 on nicotine and 14 on placebo, and withdrawals for reasons other than relapse were 8 against 3. Blood nicotine and cotinine levels on the patch were lower than expected, which the authors suggested may reflect poor adherence (Thomas 1995).

That design detail is the one people miss. The positive trial added nicotine to mesalamine. The negative trial replaced mesalamine with nicotine. Taken together, the trials suggest nicotine is at best a modest extra, not a substitute for standard treatment.

Nicotine against steroids

A further trial randomised 61 people with active UC to patches or prednisolone for six weeks, with mesalamine stopped at day 10. Among the 43 who completed, full sigmoidoscopic remission came in 6 of 19 on nicotine and 14 of 24 on prednisolone (32% vs 58%, p = 0.08). On the intention-to-treat analysis, which counts everyone randomised, there was little clear evidence of improvement in either group, except that prednisolone improved the sigmoidoscopy score significantly more. Side effects averaged 1.47 episodes per person on nicotine against 0.61 on prednisolone (Thomas 1996). The authors' own conclusion was that nicotine alone "appeared to be of only very modest benefit".

Enemas: a pilot that looked good, and a trial that did not

Because patches caused side effects through the bloodstream, the Cardiff group tried delivering nicotine directly to the colon. An open pilot in 22 non-smokers reported that 16 of the 17 who completed a month improved their symptom score, with few side effects (Green 1997). The placebo-controlled trial that followed randomised 104 people to nicotine or placebo enemas for six weeks. Remission came in 14 of 52 on nicotine (27%) and 14 of 43 on placebo (33%, p = 0.55), and the activity score improved slightly more on placebo (Ingram 2005).

Two arithmetic notes on that trial. The abstract says 104 were randomised, but the remission figures cover 95 people (52 plus 43); the abstract does not explain where the other nine went, and we could not read the full paper. And the abstract highlights a subgroup of 47 people taking only mesalamine, where remission was 9 of 25 against 4 of 21. That was not statistically significant (p = 0.20), and a subgroup of a failed trial is a reason for a new trial, not a finding. The pilot-then-failure sequence is the most useful lesson in this whole literature: open, uncontrolled studies of nicotine in UC have looked better than controlled ones every time they have been tested against each other.

What the meta-analyses make of it, and why two of them disagree

A Cochrane review pooled two placebo-controlled patch trials (71 on nicotine, 70 on placebo): 19 on nicotine and 9 on placebo reached remission after four to six weeks (odds ratio 2.56, 95% confidence interval 1.02 to 6.45). Against standard therapy with steroids or mesalamine, remission was 33 of 66 on nicotine and 34 of 63 on standard therapy, with no significant difference (odds ratio 0.77, 0.37 to 1.60). People on nicotine were more likely to stop because of side effects (odds ratio 5.82) (McGrath 2004).

A later meta-analysis reached a less favourable conclusion. Pooling three placebo-controlled trials with 233 patients, it found a relative risk of remission of 1.40 (0.63 to 3.12), not significant, and a significant excess of adverse events (1.95, 1.38 to 2.78). Against corticosteroids the relative risk was 0.74 (0.5 to 1.09). It concluded that the evidence did not support nicotine for inducing remission (Nikfar 2010).

So does nicotine work?

Put plainly: in people with active, mild to moderate UC, mostly non-smokers, nicotine patches added to mesalamine produced a modest extra benefit over four to six weeks, at the price of frequent side effects. As the only treatment, nicotine did not maintain remission and did not match prednisolone. Delivered as an enema, it failed its controlled trial. That is why Crohn's & Colitis UK states there is "no advantage to using nicotine to get Ulcerative Colitis under control, compared to standard medicines" (Crohn's & Colitis UK), and why the British guideline describes the patch trials as showing "at best modest benefit in active UC" with negative maintenance trials (Lamb 2019).

Almost all of this evidence is 20 to 30 years old and comes largely from one research group. The trials were small, and UC treatment has changed completely since, with biologics and small-molecule drugs that did not exist then. Nobody has tested nicotine against, or alongside, a modern regimen.

If nicotine is only part of it, what else in smoke might matter?

This is the question the threads argue about most. A recurring view in r/UlcerativeColitis is that "cigarettes work and patches do not", with some people describing patches and vapes failing where cigarettes succeeded, and others the reverse (r/UlcerativeColitis thread). The trial results above fit the first view better than you might expect: if nicotine were the whole story, patches delivering smoker-level nicotine should have done more. So researchers have looked at other components. All of the following is laboratory work, much of it in mice, and none of it has produced a treatment.

Nicotine does something, but maybe not what people think. Colon biopsies from a nicotine trial in 64 non-smokers found that the inflammatory signal IL-8 fell in people whose colitis improved on nicotine, but that nicotine had no effect on the expression of mucin genes (Louvet 1999). That matters because "nicotine thickens the mucus layer" is one of the most repeated explanations in the threads. At the level of gene expression, in this trial, it did not.

Carbon monoxide calms colitis in mice. Cigarette smoke contains a lot of carbon monoxide, which patches and vapes do not deliver. In mice with a form of colitis driven by the same broad type of immune response described in human UC, exposure to carbon monoxide reduced active colitis through an enzyme pathway called heme oxygenase-1 (Sheikh 2011). That is a mouse model, and carbon monoxide is poisonous, so it is an explanation, not an option.

Smoking moves mouth bacteria into the colon. A 2026 study in Gut found that in people with IBD, smoking was associated with more oral bacteria in the lining of the colon, and that people with UC who smoked had different faecal metabolites from those who had quit. When germ-free mice were colonised with one of those oral species, Streptococcus mitis, it induced a particular type of immune cell in the colon, reduced inflammation in a mouse model of UC, and worsened it in a mouse model of Crohn's (Miyauchi 2026). This is the study behind the recent headlines about mouth bacteria and colitis. It is an elegant possible explanation for why smoking pushes UC and Crohn's in opposite directions, and for why people with UC flare after quitting. The causal experiments were done in mice.

The practical upshot: if part of smoking's effect in UC comes from carbon monoxide, smoke chemistry or bacteria that ride in with it, then the part that might help is inseparable from the part that causes cancer and heart disease. That is the opposite of reassuring for anyone hoping to find the "safe ingredient".

What the guidelines actually say

No guideline we read recommends starting to smoke for ulcerative colitis. The one that addresses the question most directly is the British Society of Gastroenterology's, in its Statement 117: "Ulcerative colitis patients who continue to smoke cigarettes should be encouraged to stop. There is an increased risk of flare after stopping, and patients should be made aware of this. We suggest that they are informed that an increase in medication may be required to control their disease." It is graded a weak recommendation based on very low-quality evidence, with 95.7% agreement among the guideline group (Lamb 2019).

The same section contains a nuance the forums rarely mention. It states that nicotine gum "should only be recommended in refractory disease and as an alternative to resumption of smoking, with full discussion of its addictive nature", noting there are no trials of nicotine gum in UC, only case reports (Lamb 2019). So "no guideline supports nicotine" is slightly too strong. More precisely: one national guideline leaves room for nicotine gum in difficult-to-treat disease, as a lesser evil than going back to cigarettes, after a proper conversation. That is a specialist decision for a small group of people, not a general recommendation.

The study behind "my doctor told me to smoke"

A handful of people in the threads say a doctor told them smoking might help. The closest thing in the literature is a Chicago case series of 17 ex-smokers with refractory UC. Fifteen resumed low-dose smoking (a mean of 8.6 cigarettes a day), and 14 of those 15 were reported to maintain prolonged remission off steroids. One became addicted, was compelled to quit, flared after three years of remission, and eventually had surgery (Calabrese 2012).

Read that for what it is: 15 hand-selected people, no control group, no blinding, and outcomes judged by the team that recommended the treatment. It cannot tell you whether those people would have settled anyway, and it cannot weigh the cancer, lung and heart risk that follows years of smoking, which the study was not designed to measure. The authors themselves said smoking risks "should all be considered and discussed with patients". It is not evidence that smoking again is a sensible plan, and nobody should use it as permission.

The trade-off, in numbers

Whatever smoking does or does not do to the colon, its effect on the rest of the body is not in doubt. In a nationally representative US study of more than 200,000 adults, current smokers aged 25 to 79 died at about three times the rate of never smokers, lost more than 10 years of life expectancy, and the probability of surviving from 25 to 79 was roughly halved. People who quit between 25 and 34 regained about 10 years, and quitting before 40 reduced the excess risk of death from continued smoking by about 90% (Jha 2013).

Set that against the colitis side of the ledger, where the pooled data do not show that smoking prevents colectomy (To 2016). Three other UC-specific points belong in the same calculation.

Colon cancer surveillance. One doctor in the threads reportedly told a patient that smoking protects people with UC from colon cancer (r/UlcerativeColitis thread). We found no evidence for that. In a prospective Dutch surveillance cohort of 576 people with colonic IBD, ever smoking was not associated with recurrent colorectal neoplasia (hazard ratio 1.04, 0.75 to 1.44), but each additional 10 pack-years was associated with a 17% higher risk (1.17, 1.03 to 1.32), with no difference between Crohn's and UC in separate analyses (Wijnands 2023). That points the other way from the claim, with a dose-response.

Pouches. If you ever need surgery and a J pouch, smoking does not appear to protect it. In 327 people followed after pouch surgery for UC, smoking before, at or after the operation did not significantly change the risk of pouchitis, with a non-significant tendency towards more pouchitis in smokers (Joelsson 2006).

Surgery itself. Crohn's & Colitis UK notes that smoking increases the risk of complications after bowel surgery, including wound infections, pneumonia and sepsis, and that people with UC already have a raised risk of blood clots, which smoking adds to (Crohn's & Colitis UK).

Smoking can narrow your UC treatment options

Of the two ranking pages we read in full, Crohn's & Colitis UK gives this one line and the other does not mention it, yet it may matter more to you in practice than anything above. One class of modern UC tablets, the JAK inhibitors, carries restrictions that turn on smoking history.

In 2022 the European Medicines Agency's safety committee recommended that JAK inhibitors used for chronic inflammatory disorders, including ulcerative colitis, be used in certain groups only if no suitable treatment alternatives are available. Those groups are people aged 65 or over, people at increased risk of major cardiovascular problems, people at increased risk of cancer, and "those who smoke or have done so for a long time in the past". The medicines named include filgotinib, upadacitinib and tofacitinib (European Medicines Agency 2022).

The US prescribing information for tofacitinib carries a boxed warning stating that, for both major cardiovascular events and cancer, "patients who are current or past smokers are at additional increased risk", and asks prescribers to weigh benefits and risks particularly in current or past smokers (DailyMed tofacitinib label).

Where these warnings come from matters, so here is the chain.

• The source trial was in rheumatoid arthritis, not UC. ORAL Surveillance randomised 4,362 people with rheumatoid arthritis, aged 50 or over with at least one extra cardiovascular risk factor, to tofacitinib or a TNF inhibitor. Over a median of four years, cancers occurred in 4.2% on tofacitinib against 2.9% on the TNF inhibitor (hazard ratio 1.48, 1.04 to 2.09). Major cardiovascular events occurred in 3.4% against 2.5% (hazard ratio 1.33, 0.91 to 1.94), a confidence interval that crosses 1, so that difference on its own was not statistically significant; the trial failed to show that tofacitinib was non-inferior on either outcome. It was funded by Pfizer, which makes tofacitinib (Ytterberg 2022).
• The smoking link comes from a later analysis of that trial. A post hoc analysis found that the excess risk with tofacitinib was concentrated in people who were 65 or over or had ever smoked, with hazard ratios from 1.41 to 5.19 across outcomes, and no detectable excess in people under 65 who had never smoked. The authors report this low-risk finding was corroborated across the rheumatoid arthritis, psoriatic arthritis and UC programmes (Kristensen 2023). Six of its eight authors are Pfizer employees and stockholders, according to its competing interests statement.
• The label puts figures on it. Among current and past smokers in ORAL Surveillance, lung cancer occurred at 0.48 and 0.59 per 100 patient-years on the two tofacitinib doses against 0.27 on the TNF inhibitor (DailyMed tofacitinib label).

One precision point. Crohn's & Colitis UK phrases this as JAK inhibitors "generally" not being given to people who smoke (Crohn's & Colitis UK). The European regulator's wording is softer: use only if no suitable alternative exists. In practice both mean the same thing for a person with UC who smokes: a class of drugs that might otherwise be offered moves further down the list. With UC, where people sometimes cycle through several treatments, losing a whole class is a real cost.

Vaping, pouches, snus and heated tobacco

These come up constantly, especially from people who swapped cigarettes for something else and are now afraid to stop that too (r/UlcerativeColitis thread). The evidence is thin enough to summarise in a few lines.

Vaping. The only clinical outcome study we found compared 127 people with IBD who currently vaped nicotine against 251 who did not, looking at a composite of starting or switching a biologic, or IBD-related hospitalisation or surgery, over two years. In UC, current e-cigarette use was not associated with the outcome (odds ratio 1.05, 0.33 to 3.39). An interval that wide cannot rule out a large benefit or a large harm. The authors advised that patients be discouraged from starting to vape (Sheehan 2023). The British guideline adds that a case report found no benefit from e-cigarettes despite nicotine delivery comparable to smoking (Lamb 2019).

Nicotine pouches, snus and heated tobacco. We found no study of any of these in ulcerative colitis. In one r/UlcerativeColitis thread, a person on infliximab described urgency easing within weeks of starting nicotine pouches, while others in the same thread said pouches did nothing for them (r/UlcerativeColitis thread). When someone is also on a biologic, there is no way to know which one made the difference. The wider pouch and snus evidence is covered in our Crohn's smoking article.

Crohn's & Colitis UK's position is a useful one to hold: vapes can help people who are quitting smoking and are less harmful than cigarettes, but they are not recommended for non-smokers and are not harm-free (Crohn's & Colitis UK).

If you smoke and want to quit: how to make it safer

Quitting is the right call for almost everyone, and it is still worth planning because the flare risk is real. The British guideline's advice is specific: patients should be told about the flare risk, and "for patients who do plan to stop, a plan to mitigate the risk of worsening disease by an increase in their treatment should be discussed" (Lamb 2019). Crohn's & Colitis UK puts it more plainly: your IBD team can work with you on a treatment plan before you stop, which might include more medication or closer monitoring (Crohn's & Colitis UK).

So a sensible sequence looks like this:

1. Tell your IBD team you plan to quit, before the quit date. Ask whether they want a baseline calprotectin or blood test first, and what they would change if symptoms return. If you have a baseline, a later rise means more; our guide to what calprotectin levels mean in UC explains how to read one.
2. Use real quit support. The British guideline recommends that everyone with IBD who smokes be offered a smoking cessation service, combining behavioural support with medication such as nicotine replacement, bupropion or varenicline (Lamb 2019). Across 133 trials with 64,640 people, any form of nicotine replacement raised the chance of quitting by about 55% compared with control (relative risk 1.55, 1.49 to 1.61) (Hartmann-Boyce 2018). Choosing among these is a conversation with your doctor, pharmacist or stop-smoking service.
3. Know what you are watching for, and for how long. The risk window in the onset data runs for years, not weeks (Higuchi 2012). Our guide to telling whether your UC is flaring covers the signs that matter.

Does nicotine replacement protect you from the post-quit flare? People reasonably hope it will, since patches deliver nicotine. We could find no trial that tested this. The indirect evidence is not encouraging: in the maintenance trial, nicotine patches on their own did no better than placebo at keeping people in remission (Thomas 1995), and several people in the threads describe flaring despite patches or vapes (r/UlcerativeColitis thread). Use nicotine replacement because it helps you quit, not because you expect it to hold your colitis.

What to track if you quit

The point of tracking around a quit is to give your IBD team early, specific information rather than a vague sense that things are worse. What is worth recording, daily and briefly:

• Stool frequency compared with your usual, and whether any are at night.
• Visible blood, yes or no.
• Urgency, including near-misses; it is often the first thing to change. Our article on urgency in UC covers why.
• Cigarettes or nicotine use, including slips, patches, gum, vapes or pouches, and the date you stopped each.
• Anything else changing at the same time: new medications, antibiotics, a stomach bug, a stressful month. A quit rarely happens in isolation, and a flare after it is not automatically caused by it.

Because the risk runs over months, a quick daily log is more useful than trying to remember at an appointment. Clairop is one way to keep that log: it records symptoms and daily factors alongside each other and produces a one-page GI visit report you can bring to your IBD team (how it works). A paper diary does the same job if you keep it.

A worked example: what tracking can and cannot show

This is an illustration, not a real case. Imagine someone with left-sided UC in remission on mesalamine who decides to quit after years of smoking. Before the quit date they tell their IBD nurse, who arranges a calprotectin test and agrees a plan: if bleeding returns for more than a few days, call in rather than waiting for the next clinic.

For the first six weeks their log shows nothing new: one or two formed stools a day, no blood. In week nine, stool frequency creeps from two to four a day, urgency appears on three mornings, and there is a streak of blood twice in one week. The log also shows they finished a course of antibiotics for a chest infection in week seven.

What the log can do here is give the IBD team a clean timeline: when the change started, how fast it moved, and the two plausible contributors (the quit and the antibiotics, plus the possibility of an infection, which the team may want to test for). What it cannot do is tell anyone which of those caused the change. Nor can it tell them whether this is a flare driven by inflammation until a calprotectin or other test shows it. The response, adjusting treatment early under the agreed plan, is the same either way, and it happens weeks sooner than it would have without the record.

The wrong lesson from this example would be "quitting caused a flare, so smoke again". The right one is that a planned quit, with a way to spot a flare early, turns an alarming experience into a manageable one.

When to see a doctor promptly

Contact your IBD team or doctor promptly, whether or not you have recently changed your smoking, if you have:

• blood in your stool that is new, increasing or lasting more than a couple of days
• more than six bloody stools a day, a fever, a fast heart rate, or feeling faint (these can signal a severe flare, and our guide on when to go to hospital for a UC flare covers what counts as an emergency)
• unexplained weight loss, night-time diarrhoea waking you from sleep, or signs of anaemia such as breathlessness and exhaustion
• severe or worsening abdominal pain or a swollen, tender abdomen
• sudden breathlessness, chest pain, or a swollen, painful leg or arm while taking tofacitinib or another JAK inhibitor, which the tofacitinib label lists as possible signs of a blood clot that need a call to your doctor right away
• any symptoms that are new and you have not yet been diagnosed, especially if they started after 50 or you have a family history of bowel cancer or IBD

And if you are considering going back to smoking to control a flare, that is itself a reason to talk to your gastroenterologist promptly, because it usually means your current treatment is not working well enough.

Myths, from both directions

"Smoking cures ulcerative colitis." Nothing cures UC, and the pooled data do not show that smokers have fewer colectomies or flares (To 2016).

"Smokers are definitely protected from getting UC." The meta-analysis says lower odds; the largest prospective cohort found no statistically significant protection in current smokers (Higuchi 2012). The raised risk after quitting is the firmer finding.

"Nicotine patches were proven to work." For a few weeks, added to mesalamine, in small trials, with side effects. Not as maintenance and not better than prednisolone (Thomas 1995; Thomas 1996).

"It's the mucus: nicotine thickens the colon's protective layer." Biopsies from a nicotine trial found no change in mucin gene expression (Louvet 1999). The mechanism is genuinely unknown.

"Smoking protects against colon cancer in UC." We found no evidence for this, and a prospective IBD surveillance cohort linked more pack-years with more recurrent neoplasia (Wijnands 2023).

"Smoking helps IBD." Only possibly in UC. In Crohn's disease it is linked with worse outcomes, which our Crohn's smoking guide sets out.

"Quitting gave me colitis, so quitting was a mistake." The timing is real and well documented. But the flare risk after quitting is treatable, the risks of continuing to smoke are not reversible, and the British guideline still recommends stopping with a plan in place (Lamb 2019).

"Vaping is the safe way to get the benefit." One small study found no association in either direction, with a very wide interval (Sheehan 2023). Nobody has shown a benefit.

The bottom line

The idea that smoking helps ulcerative colitis started from a real observation: UC is uncommon in current smokers in many studies, and it often begins after someone quits. That second part is the most solid thing in this whole literature. But once you have UC, the best pooled evidence shows no significant benefit from smoking on the outcomes that matter. The nicotine trials showed a modest, short-lived effect as an add-on and nothing as a replacement. The mechanisms under study, carbon monoxide and mouth bacteria among them, are tied to the most harmful parts of smoke.

If you smoke, the evidence supports quitting with a plan: tell your IBD team first, get proper quit support, and track closely for the months afterwards. If you have already quit and your colitis started or worsened, that is a known pattern with known treatments, and your team should hear about it. If you are weighing smoking again, you are not alone in the question. Take it to your gastroenterologist rather than a forum, because the answer involves your particular disease, your treatment history and options such as the drugs you may lose access to by smoking.

For more on reading your own disease activity, see our guides to how long a UC flare lasts and UC symptoms that continue in remission, and for what to raise at your next appointment, questions to ask your gastroenterologist about colitis.